Scarica l'app Stockscreener
1.18
6.31%
0.07
Dopo l'orario di chiusura:
1.19
0.01
+0.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Precedente Chiudi:
$1.11
Aprire:
$1.12
Volume 24 ore:
464.22K
Relative Volume:
0.39
Capitalizzazione di mercato:
$126.40M
Reddito:
$32.29M
Utile/perdita netta:
$-39.12M
Rapporto P/E:
-3.2161
EPS:
-0.3669
Flusso di cassa netto:
$-29.51M
1 W Prestazione:
+12.38%
1M Prestazione:
-8.53%
6M Prestazione:
+46.04%
1 anno Prestazione:
-17.48%
Intervallo 1D:
$1.12
$1.18
Intervallo di 1 settimana:
$1.05
$1.18
Portata 52W:
$0.6434
$1.865
Maxcyte Inc Stock (MXCT) Company Profile
Nome
Maxcyte Inc
Settore
Industria
Telefono
301-517-5556
Indirizzo
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.18 | 109.26M | 32.29M | -39.12M | -29.51M | -0.3669 |
ABT
Abbott Laboratories
|
107.81 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
339.03 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
87.16 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.31 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.72 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-08-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Iniziato | Stephens | Overweight |
| 2023-11-29 | Iniziato | Craig Hallum | Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-24 | Iniziato | BTIG Research | Buy |
| 2021-08-24 | Iniziato | Cowen | Outperform |
| 2021-08-24 | Iniziato | Stephens | Overweight |
| 2021-08-24 | Iniziato | Stifel | Buy |
| 2021-08-24 | Iniziato | Wedbush | Outperform |
| 2021-08-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Maxcyte Inc Borsa (MXCT) Ultime notizie
MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MaxCyte Inc (MXCT) Institutional Confidence - TradingKey
MaxCyte Inc (MXCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MaxCyte Inc (MXCT) Cash Flow - TradingKey
MXCT|MaxCyte Inc|Price:1.080|Chg%:-0.040 - TradingKey
MaxCyte Inc (MXCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MaxCyte, Inc. Revenue Breakdown – DUS:MYE0 - TradingView
MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MaxCyte Inc (MXCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
MaxCyte stock surges on Genentech technology license deal By Investing.com - Investing.com South Africa
MaxCyte stock surges on Genentech technology license deal - Investing.com
MaxCyte Enters Technology License Partnership With Genentech - marketscreener.com
Genentech licenses MaxCyte cell engineering technology - Investing.com
MaxCyte licenses cell therapy tech to Genentech for research and manufacturing support - Pluang
Genentech licenses MaxCyte cell engineering technology By Investing.com - Investing.com Canada
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development - The Manila Times
Genentech Gets Access to MaxCyte Cell-Engineering Platforms - Stock Titan
MaxCyte (MXCT) Proxy filing Summary - Quartr
MaxCyte (MXCT) The 44th Annual William Blair Growth Stock Conference Summary - Quartr
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 - The Manila Times
MaxCyte to report Q2 2026 financial results on August 12 - scanx.trade
Enterprise value to revenue forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
Price to sales forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
Price to earnings forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
ETFs Investing in MaxCyte, Inc. Stocks - TradingView
MaxCyte Inc focuses on cell engineering. Nasdaq-listed MXCT targets long-term growth - Ad-hoc-news.de
MaxCyte (MXCT) Stephens Annual Investment Conference Summary - Quartr
Enterprise value to EBITDA forward of MaxCyte, Inc. – NASDAQ:MXCT - TradingView
MaxCyte stock leans on platform demand. Nasdaq listing stays central. - ad-hoc-news.de
Price to sales forward of MaxCyte, Inc. – LS:A2AGVE - TradingView
Enterprise value to revenue forward of MaxCyte, Inc. – LS:A2AGVE - TradingView
Price to book forward of MaxCyte, Inc. – NASDAQ:MXCT - TradingView
MYE0 Forecast — Price Target — Prediction for 2027 - TradingView
MaxCyte, Inc. Actuals & Estimates (NASDAQ:MXCT) - TradingView
MXCT Forecast — Price Target — Prediction for 2027 - TradingView
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering - Business Wire
Form 4 MaxCyte Inc For: 22 June By Investing.com - Investing.com South Africa
MaxCyte (MXCT) grants RSUs and stock options to director - Stock Titan
MaxCyte (MXCT) director awarded RSUs and stock options in annual grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and options in annual equity grant - Stock Titan
MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award - Stock Titan
MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and 49,579 stock options in new grant - Stock Titan
MaxCyte (MXCT) director Patrick Balthrop receives RSU and stock option grants - Stock Titan
MaxCyte (MXCT) director receives RSU and stock option grant - Stock Titan
MXCT Q1 2026 Earnings: Strong EPS Beat Drives Share Price HigherOne-Time Loss Impact - dars.gov.et
Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
Maxcyte Inc Azioni (MXCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maxcyte Inc Azioni (MXCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
0.67%
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):